← All trials
NCT02876328
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Mar 31, 2017
- Primary completion
- Mar 1, 2019
- Completion date
- Mar 1, 2019
- First posted
- —
- Last posted
- —
- Enrollment
- 5500
- Arms / groups
- 5 / —
- Source
- AACT · pre-existing
Sponsors
- National Institute of Allergy and Infectious Diseases (NIAID)Lead sponsor
- Institut National de la Santé Et de la Recherche Médicale, FranceOverall official - principal investigator
- Redemption HospitalOverall official - principal investigator
- University of Sierra LeoneOverall official - principal investigator
- Institut National de la Santé Et de la Recherche Médicale, FranceCollaborator
- University of LondonCollaborator
- The Liberia-US Clinical Trials Partnership Program, Partnership for Research on Ebola Virus in Liberia ProjectCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.